Kabra Drugs Ltd Q4 FY26 results press release summary

Results press release of 30 May 2026, summarised by AI from the filing.

EBITDA and PAT turned positive in FY26 compared to losses in the previous financial year.

Key takeaways

1. Profitability EBITDA and PAT turned positive in FY26 compared to losses in the previous financial year.
2. Pharma expansion Branded generic & generic pharma manufacturing and marketing expansion in phases via Mr. Franchise, Phase 1 across South India.
3. Defence & AI Company to initiate DGFT approval process for SCOMET License and establish AI & Defence Technology R&D facility at Cactus TECCI Park, Chennai.

Original filing on BSE

Kabra Drugs Ltd earnings call, investor presentation and press release summaries

• Q4 FY26: Results press release (30 May 2026)